Brokers Issue Forecasts for NTLA FY2026 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at Brookline Capital Markets reduced their FY2026 earnings estimates for Intellia Therapeutics in a research note issued on Thursday, November 5th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of ($2.92) for the year, down from their previous estimate of ($2.84). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.21) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics’ FY2029 earnings at $13.90 EPS and FY2030 earnings at $23.26 EPS.

A number of other equities analysts have also recently issued reports on the stock. Wedbush boosted their price objective on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Wednesday, September 9th. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Thursday, October 15th. Wolfe Research cut Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price on the stock. in a research note on Wednesday, July 15th. Finally, Barclays initiated coverage on Intellia Therapeutics in a report on Tuesday, October 6th. They set an “underweight” rating and a $8.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $21.44.

Intellia Therapeutics Stock Up 6.7%

Shares of NTLA opened at $12.11 on Tuesday. The stock has a market capitalization of $1.70 billion, a P/E ratio of -3.61 and a beta of 1.83. Intellia Therapeutics has a twelve month low of $7.95 and a twelve month high of $18.48. The firm has a fifty day simple moving average of $12.08 and a two-hundred day simple moving average of $13.04.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 5th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The firm had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $9.74 million. During the same period in the previous year, the firm earned ($0.92) earnings per share. The firm’s quarterly revenue was down 47.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Wellington Grp LLC lifted its position in shares of Intellia Therapeutics by 65.3% in the 3rd quarter. Wellington Grp LLC now owns 111,876 shares of the company’s stock worth $1,349,000 after purchasing an additional 44,188 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Intellia Therapeutics by 64.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 210,990 shares of the company’s stock valued at $2,545,000 after purchasing an additional 82,737 shares in the last quarter. Gen Wealth Partners Inc boosted its stake in shares of Intellia Therapeutics by 34.0% during the 3rd quarter. Gen Wealth Partners Inc now owns 82,177 shares of the company’s stock valued at $991,000 after purchasing an additional 20,834 shares in the last quarter. Fulcrum Asset Management LLP purchased a new position in shares of Intellia Therapeutics during the third quarter valued at about $165,000. Finally, Parallel Advisors LLC increased its position in shares of Intellia Therapeutics by 267.0% during the third quarter. Parallel Advisors LLC now owns 2,268 shares of the company’s stock valued at $27,000 after buying an additional 1,650 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 9,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total value of $107,910.00. Following the completion of the sale, the chief executive officer owned 1,138,064 shares of the company’s stock, valued at $13,645,387.36. This trade represents a 0.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 3.50% of the stock is owned by insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA.

Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.